Lametec 25 DT

Lamotrigine is a phenyltriazine anticonvulsant medication primarily used to treat epilepsy and bipolar disorder by stabilizing neuronal membranes and inhibiting excessive electrical activity in the brain.[1] It is approved for adjunctive therapy in partial seizures, primary generalized tonic-clonic seizures, and Lennox-Gastaut syndrome in patients aged 2 years and older, as well as for conversion to monotherapy in partial seizures in patients aged 16 years and older, and for maintenance treatment of bipolar I disorder to delay mood episodes in adults aged 18 years and older.[2] First approved by the U.S. Food and Drug Administration (FDA) in 1994 for epilepsy, it was later approved in 2003 for bipolar disorder, marking the first new maintenance treatment for the condition since lithium.[1] Lamotrigine works by selectively inhibiting voltage-gated sodium channels, which reduces the release of excitatory neurotransmitters like glutamate and aspartate, thereby preventing seizure spread and stabilizing mood.[1] It is available in various oral formulations, including immediate-release tablets (typically administered in divided doses twice daily), extended-release tablets (designed for once-daily dosing), chewable tablets, orally disintegrating tablets, and oral suspension, with a bioavailability of approximately 98% and a half-life ranging from 14 to 59 hours. Multiple studies indicate that once-daily dosing with the extended-release formulation has a similar safety and tolerabili